CJC-1295 (also known as DAC:GRF) is a synthetic analogue of growth hormone-releasing hormone (GHRH). It stimulates the GHRH receptor at the pituitary gland, triggering pulsatile growth hormone (GH) release. Through Drug Affinity Complex (DAC) technology, CJC-1295 covalently binds albumin, extending its half-life to approximately 7–10 days.
Ipamorelin belongs to the class of ghrelin mimetics (GHRPs). It binds to the GHSR-1a receptor (ghrelin receptor) and stimulates GH release via a signalling pathway independent of GHRH. Ipamorelin's high selectivity for GHSR-1a without notable influence on cortisol or prolactin makes it particularly interesting in research circles.
Simultaneous activation of both signalling pathways leads to synergistic GH release that exceeds the sum of the individual effects. This principle of dual pituitary stimulation is well documented and explains the popularity of this combination in research on the growth hormone axis system.
Ipamorelin mimics the short-term GH pulse while CJC-1295 elevates basal GHRH stimulation. This combination generates a more physiological GH secretion profile than high-dose monotherapies.
In preclinical research, both peptides are used to study the somatotropic axis (GH/IGF-1 axis) — a system with wide-ranging effects on protein synthesis, fat metabolism, bone development and immune function. Studien Peptide offers CJC-1295 and Ipamorelin as high-purity individual compounds for research purposes.
What do we know in 2026 about the lipolytic mechanisms of HGH Fragment 176-191 (AOD9604)? Current research data on beta-3-AR and fat breakdown.
Tesamorelin has been FDA-approved since 2010. What has research learned since then? New findings on lipodystrophy, myosteatosis and MASLD.
TB-500 and BPC-157 are frequently used in combination in research laboratories. What science knows about their complementary mechanisms.